Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00702364 · ClinicalTrials.gov registry record · NA
Efficacy Study of Strattera for Treating Attention Disorders in Traumatic Brain Injury (TBI)
A NA study of Traumatic Brain Injury, sponsored by Craig Hospital.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT00702364: Completed NA study of Traumatic Brain Injury, sponsored by Craig Hospital.
NCT00702364 is a NA study of Traumatic Brain Injury that has completed, run by Craig Hospital. The registered enrollment target is 60 participants, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00702364, a NA study of Traumatic Brain Injury, has completed, sponsored by Craig Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Atomoxetine is the only medication that is currently approved by the FDA for the treatment of attention deficit hyperactivity disorder in adults. It has gained recent interest as an alternative medication for treating attentional problems related to traumatic brain injury (TBI), but it's effectiveness in this population has not been studied. There are a number of advantages of Atomoxetine over traditional neuro-stimulant medications currently used for attentional disorders after traumatic brain injury. This study will use a randomized double-blind placebo-controlled crossover design to investigate the efficacy of atomoxetine to improve attention, behavioral function, and depression in adults with TBI
Primary Outcome
Cognitive Drug Research (CDR) Computerized Cognitive Assessment System \[19\] is comprised of a battery of computer-controlled tasks administered on a laptop computer with parallel forms of the tests being presented on each testing session. The Power of Attention factor of the CDR was selected as the primary outcome measure because of its strong psychometric properties in other drug studies with cognitively compromised populations. Instead of utilizing a t-test to compare treatment and control
Conditions Studied
Interventions
- DRUG placebo
- DRUG atomoxetine
Study Locations (1)
Colorado
- Craig Hospital - Englewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-01 |
| Est. Completion | 2012-03 |
| Phase | NA |
What the finished NCT00702364 record still lists
NCT00702364 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Traumatic Brain Injury appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00702364 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT00702364 about?
NCT00702364 is a clinical study titled "Efficacy Study of Strattera for Treating Attention Disorders in Traumatic Brain Injury (TBI)". Atomoxetine is the only medication that is currently approved by the FDA for the treatment of attention deficit hyperactivity disorder in adults. It has gained recent interest as an alternative medication for treating attentional problems related to traumatic brain injury (TBI), but it's effectivene...
What is the current status of trial NCT00702364?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2008-01. Estimated completion is 2012-03.
What conditions does trial NCT00702364 study?
This clinical trial studies the following conditions: Traumatic Brain Injury.
What interventions are being tested in trial NCT00702364?
The interventions under investigation include: placebo (DRUG), atomoxetine (DRUG).
Who is sponsoring clinical trial NCT00702364?
This trial is sponsored by Craig Hospital, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00702364 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Traumatic Brain Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00702364's enrollment target sits among peer trials
60 103rd of 171 higher than 61 of 171 other Traumatic Brain Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Traumatic Brain Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
tPBM in Older Adults With Traumatic Brain Injury
RECRUITING · NA
-
Carbon Dioxide Administration and Brain Waste Clearance
RECRUITING · NA
-
TMS-fNIRS Personalized Dosing
RECRUITING · NA
-
Community-based Implementation of Online EmReg
RECRUITING · NA
-
Evaluation of the Abbott i-STAT TBI Biomarker Test
RECRUITING · NA
-
Long-term Brain Stimulation of the Motor Ventral Thalamus (VOP/VIM) to Improve Motor Function
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia